Literature DB >> 12397459

Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study.

Georg Zettinig1, Georg Hanselmayer, Barbara J Fueger, Andrea Hofmann, Christian Pirich, Johannes Nepp, Robert Dudczak.   

Abstract

Impairment of the lacrimal glands after external radiation has been well documented, but there are only a few reports on the effects of radioiodine therapy on the lacrimal glands. Long-term effects of high-dose radioiodine therapy on tear secretion have not previously been studied. We investigated 175 eyes of 88 patients with a history of radioiodine therapy for thyroid carcinoma (68 females, 20 males; mean age 55+/-16 years, range 17-81 years) and compared them with a sex- and age-matched control group ( n=39). All patients had been given at least 2.96 GBq iodine-131 (maximal administered activity 22.3 GBq (131)I). An ophthalmological investigation was performed 64+/-71 months (range 3-317 months) after initial radioiodine therapy by a single ophthalmologist. Lacrimal gland function was evaluated with three different function tests. External eye morphology was considered, and detailed ophthalmological history-taking was performed. Patients with factors known to affect lacrimal gland function (contact lenses, autoimmune disorders, history of additional radiation exposure) were excluded from the study. A total of 81 patients (92%) had at least one abnormal function test indicating impaired lacrimal gland function. Schirmer's tear test was decreased (<10 mm/5 min) in 47 of the 88 patients and definitely abnormal (<5 mm/5 min) in 35 patients. A tear film break-up time of <10 s was found in 78 patients, and 62 patients had a definitely abnormal break-up time of <5 s. The lacrimal lipid layer was impaired in 43 patients. The function tests were all significantly altered in the study group as compared with the controls ( P<0.005, P<0.001, P<0.001, respectively). Both subjective symptoms of dry eye ( P<0.01) and changes in the external eye morphology ( P<0.001) were significantly more prevalent in the study group. Our findings suggest that in the majority of patients, lacrimal gland function may be permanently impaired after high-dose radioiodine therapy. All three layers of the tear film are involved and there is a pronounced long-term effect on the tear film stability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12397459     DOI: 10.1007/s00259-002-0969-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  14 in total

1.  Early and late immunohistochemical and ultrastructural changes associated with functional impairment of the lachrymal gland following external beam radiation.

Authors:  Samer G Hakim; Christina Schroder; Gerd Geerling; Isabel Lauer; Thilo Wedel; Hartwig Kosmehl; Oliver Driemel; Hans-Christian Jacobsen; Thomas Trenkle; Dirk Hermes; Peter Sieg
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

2.  Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study.

Authors:  Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

3.  (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.

Authors:  Kuan-Yin Ko; Chia-Hung Kao; Cheng-Li Lin; Wen-Sheng Huang; Ruoh-Fang Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

4.  Looking under the hood of "the Cadillac of cancers:" radioactive iodine-related craniofacial side effects among patients with thyroid cancer.

Authors:  Samantha A Diamond-Rossi; Jacqueline Jonklaas; Roxanne E Jensen; Charlene Kuo; Selma Stearns; Giuseppe Esposito; Bruce J Davidson; George Luta; Gary Bloom; Kristi D Graves
Journal:  J Cancer Surviv       Date:  2020-06-06       Impact factor: 4.442

5.  Pharmacological prevention of radiation-induced dry eye-an experimental study in a rabbit model.

Authors:  Julia Beutel; Christina Schroder; Katharina von Hof; Dirk Rades; Hartwig Kosmehl; Thilo Wedel; Peter Sieg; Gerd Geerling; Samer George Hakim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-21       Impact factor: 3.117

Review 6.  Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view.

Authors:  Livia Lamartina; David S Cooper
Journal:  Endocrine       Date:  2015-01-10       Impact factor: 3.633

7.  Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.

Authors:  Jacqueline Jonklaas
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

8.  Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy.

Authors:  Richard Crevenna; Georg Zettinig; Mohammad Keilani; Martin Posch; Manuela Schmidinger; Christian Pirich; Martin Nuhr; Michael Wolzt; Michael Quittan; Veronika Fialka-Moser; Robert Dudczak
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

9.  Salivary Function after Radioiodine Therapy: Poor Correlation between Symptoms and Salivary Scintigraphy.

Authors:  Jacqueline Jonklaas; Hong Wang; Giuseppe Esposito
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-17       Impact factor: 5.555

10.  Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer.

Authors:  Pablo Florenzano; Francisco J Guarda; Rodrigo Jaimovich; Nicolás Droppelmann; Hernán González; José M Domínguez
Journal:  Int J Endocrinol       Date:  2016-10-27       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.